Professional Marketing briefs: June 2013

Share this article:
Professional Marketing briefs: June 2013
Professional Marketing briefs: June 2013

Pfizer told investors at its first-quarter marketing call that a Xeljanz DTC marketing campaign is in the works for summer and that its promotional efforts among physicians—including 28-day sample packs and sales reps—has resulted in repeat prescriptions and pickup among post-methotrexate and anti-TNF patients. The company also said the drug has had broader reimbursement than anticipated.

Amgen reached a $25 million settlement with the U.S government for marketing practices around its anemia drug Aranesp. Allegations include kickbacks to long-term care pharmacies to favor Aranesp over other treatments as well as for off-label indications. The Department of Justice alleged that Amgen offered rebates for pharmacies which helped to improve Aranesp's market share.

Eli Lilly and Merck will put more person-to-person sales power behind their diabetes franchises. Lilly stated its intent before releasing its first-quarter earnings report, in tandem with an announcement that it was cutting sales support for Cymbalta and Evista. Merck has decided more of its US reps need to be dedicated only to Januvia, which saw sales slide 4% during the quarter.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Agency Gallery

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters